SCHEMBL2196882

SCHEMBL2196882

O=C1Nc2ccc(F)cc2C1=C1OCc2nc(CCN3CCOCC3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.45
PDGFRB P09619 12/20 0.45
KIT P10721 11/20 0.45
LRRK2 Q5S007 2/20 0.44
FLT3 P36888 3/20 0.41
FGFR1 P11362 2/20 0.41
MAP4K4 O95819 2/20 0.36
EGFR P00533 2/20 0.36
MAPK9 P45984 2/20 0.36
CSNK1D P48730 2/20 0.36
PRKD2 Q9BZL6 2/20 0.36
SLK Q9H2G2 2/20 0.36
ERBB2 P04626 1/20 0.36
TLK2 Q86UE8 2/20 0.36
RIOK2 Q9BVS4 2/20 0.36
TLK1 Q9UKI8 2/20 0.36
FLT1 P17948 2/20 0.36
BMPR1B O00238 1/20 0.36
PLK4 O00444 1/20 0.36
STK25 O00506 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225668 1.00 KDR (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2196880 1.00 KDR (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL12225681 0.95 PDGFRB (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2199737 0.95 PDGFRB (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2199742 0.95 PDGFRB (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2535738 0.92 FLT3 (0.41) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2199395 0.92 FLT3 (0.41) KDRPDGFRBKITLRRK2FLT3
SCHEMBL12225676 0.92 FLT3 (0.41) KDRPDGFRBKITLRRK2FLT3
SCHEMBL12225650 0.91 LRRK2 (0.45) KDRPDGFRBKITLRRK2FLT3
SCHEMBL2199801 0.91 LRRK2 (0.45) KDRPDGFRBKITLRRK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US claimed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US claimed
US-8455535-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2013-06-04 US disclosed
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors ALLERGAN, INC. (US) 2011-10-20 US disclosed
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US disclosed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors REN, JAK2, ABL1 KDR 25/4885PDGFRB 11/4885KIT 367/4885
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS REN, JAK2, ABL1 KDR 25/4885PDGFRB 11/4885KIT 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.